SAN DIEGO—Imprimis Pharmaceuticals (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, has entered into an licensing agreement for the exclusive worldwide rights to Klarity, a patented ophthalmic topical solution and gel technology for patients with dry eye disease (DED). Klarity is designed to protect and rehabilitate the ocular surface following ophthalmic surgery, contact lens wear, or in patients with moderate to severe DED. The Klarity formulation is preservative-free and can be formulated to any viscosity, ranging from a topical drop or gel to a dispersive viscosurgical device, Imprimis said.

The technology was developed by Richard L. Lindstrom, MD, a world-renowned cataract and refractive surgeon, inventor and consultant to numerous private and public ophthalmic companies. Under the terms of the agreement, Imprimis will pay Dr. Lindstrom an upfront fee, milestone payments, and royalty payments on product sales.

Mark L. Baum, CEO of Imprimis, remarked, “This agreement further strengthens our growing ophthalmology portfolio and provides us the opportunity to enter a market with significant growth potential.”